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The etiology of Langerhans cell histiocytosis
(LCH), a mix between immune dysregulation,
inflammation, and malignancy, remains unclear.1-4
In half of the patients, an oncogenic BRAF mutation
is found.3 Because of the diversity of symptoms, the
diagnosis of LCH, as defined by the Histiocyte
Society, is often made with considerable delay.
Multisystemic LCH, affecting 2 or more organ
systems and ‘‘risk organs,’’ like the hematopoietic
system, the spleen, liver, and central nervous system,
implies a worse prognosis.1,3-6 To raise the
awareness of multisystemic LCH, the case of an
elderly patient is presented and a new therapeutic
scheme with pioglitazone (peroxisome proliferator-
eactivated receptor-g [PPAR-g] agonist), etoricoxib
(COX-2 inhibitor), and trofosfamide (alkylating
medium) is described.CASE PRESENTATION
A 77-year-old man presented with plaques and
ulcerations in his armpits and groin, crusts and
papules at the scalp, inflamed oral mucosa, hearing
deficiency, otorrhea, and productive cough
for 4 months (Fig 1). The patient had been
a smoker (50 pack-years). During a dental
extraction, a biopsy specimen from the jaw bone
was taken, and immunohistochemical-positive
CD1ae and CD207estains proved the diagnosis of
LCH (Figs 2-4).
The diagnosis of LCH with a BRAF-V600E mu-
tation was proven by skin biopsy. Birbeck granules
were not detected. In an ultrasound scan, enlarged
lymph nodes were found cervically, axillarily, and
inguinally. With normal liver function results, thethe Department of Dermatology, University Medical Center
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with hepatic steatosis and not typical for LCH. A
thoracic computed tomography (CT) scan showed
pulmonary cystic nodules. Pulmonary function
testing was without pathologic findings. No signs
of diabetes insipidus were found: the patient did
not suffer from polyuria or polydipsia. Blood
count, thyroid-stimulating hormone, serum/urine
osmolality, and a CT scan of the pituitary were
inconspicuous. A CT scan showed involvement of
the mastoid cells, which explained the otorrhea. A
biopsy of the mastoid showed a co-expression of
CD1a and S100 on Langerhans cells.
A multisystemic LCH with involvement of the
lungs, bones, skin, and lymph nodes was diagnosed.
A topical disinfectant (Octenisept, Sch€ulke & Mayr
GmbH, Norderstedt, Germany) and betamethasone
cream were administered. We combined it with a
systemic therapy (trofosfamid 50 mg 3 times a day;
and pioglitazon 15 mg and etoricoxib 30 mg once a
day) starting in October 2015 and continuing
currently.
DISCUSSION
LCH in adults is seen with an incidence of
8:100,000. We report on an elderly patient with
multisystemic LCH, treated by a novel cytotoxic,
anti-inflammatory, and antiangiogenic therapy.JAAD Case Reports 2017;3:162-4.
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Fig 1. Clinical appearance.
Fig 2. Hematoxylin eosin staining. Fig 3. CD1a staining.
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microscopy is pathognomonic for LCH. The pres-
ence of CD1ae and CD207e antigens can confirm the
diagnosis.4,6 LCH can be diagnosed if at least 2 stains
for ATPase, S-100 protein, a-D-mannosidase, or
binding of peanut lectin on lesional cells are posi-
tive.6 Similar to our patient, in half of all LCH cases an
oncogenic BRAF mutation is found.3 CD1ae and
CD207e antigens were detected in our patient;
Birbeck granules were not seen. Suffering from
multisystemic LCH, our patient had osseous, pulmo-
nary, cutaneous lesions together with an involve-
ment of the lymph nodes:
Most LCH-related bone lesions are found in the
skull, spine, or mandible.1 Our patient had lesions in
the mandible and in the mastoid cells. Infiltration of
the skull is found in approximately 25% to 45% of the
patients. The temporal bone is affected in up to 60%.7
Loosening of the teeth was caused by gingival and
alveolar bone infiltration. Tooth extractions should
be avoided in these patients.3 Bone lesions may be
treated by surgery, intralesional injection of methyl-
prednisolone, or radiotherapy.3,4
Pulmonary involvement is an atypical feature of
multisystemic LCH. This finding could be related tosmoking, as more than 90% of LCH patients are
smokers, and cessation of smoking can be
curative.3,7
Cutaneous LCH is often the first symptom of
multisystemic LCH. Scalp lesions with small papules
and axillary and inguinal involvement were found in
our patient.3 In skin lesions, the efficacy of topical
corticosteroids has never been proven.
In 1 of 20 patients, mainly cervical lymph nodes
are infiltrated.7 Our patient showed an echographic
enlargement of cervical, axillary, and inguinal lymph
nodes.
Multisystemic LCH necessitates systemic therapy,
often vinblastine, 6 mg/m2, and prednisone, 40 mg/
m2/d. In case of progression after 6 weeks, patients
should be treated for another 6 weeks or should be
converted to a combination of 2-chlorordeoxadeno-
sine and cytarabine.4
A hematopoietic stem cell transplant may offer a
chance for a cure.1 BRAF inhibitors like vemurafe-
nib are new therapeutic options.3 An overexpres-
sion of prostaglandins and cyclooxygenase 2 in
pathologic Langerhans cells is described. The
activity of Langerhans cells is regulated by the
PPAR-g. These findings lead to a new therapeutic
Fig 4. CD207 staining.
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icoxib (COX-2 inhibitor), and trofosfamide (alkylat-
ing medium),8,9 which was applied in our patient.
He tolerated the therapy without any side effects.
During the progression of therapy, all skin lesions
healed and the pulmonary and osseous manifesta-
tions have shown a remission at the last staging
examinations.
LCH is a rare and serious disease often diagnosed
late because of its manifold symptoms.3,10 The
prognosis depends on the number of organs
involved, the presence of organ dysfunction, and
the patient’s age. Often LCH follows a benign course,
but some patients suffer from progressive disease
with high mortality. These patients must be identi-
fied in time for treatment.REFERENCES
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